Gilead Sciences, Inc. (Nasdaq: GILD) recently announced that data through 144 weeks supporting the efficacy and tolerability of its oral antiviral drug Hepsera(R) (adefovir dipivoxil) in patients chronically infected with hepatitis B "e" antigen-negative (HBeAg-negative) chronic hepatitis B were published in the June 30th edition of the New England Journal of Medicine (NEJM). Continued viral suppression and changes in laboratory markers of liver function were evaluated through three years. Medicure Inc. (AMEX: MCU), a cardiovascular drug discovery and development company, in conjunction with the University of Manitoba and the University of Ottawa Heart Institute, is pleased to announce that they have received a Collaborative Research and Development grant from the National Sciences and Engineering Research Council of Canada (NSERC) for the development of their novel cholesterol lowering platform.

U.S. Biodefense Inc. (OTCBB: UBDE), a Department of Defense central contractor and technology transfer company, and Diamond I Inc., a developer of wireless handheld gaming products, announced recently the signing of a patent listing and Tech Transfer alliance agreement. Dyax Corp. (Nasdaq: DYAX) recently announced positive topline results from its completed Phase I trial to evaluate safety and pharmacokinetics (PK) of subcutaneously administered DX-88 in normal volunteers. The Company also announced the presentation today at the World Allergy Congress in Munich of positive interim results from the first 120 attacks of hereditary angioedema (HAE) treated with intravenously administered DX-88 in its open-label, repeat dosing Phase II trial referred to as EDEMA2.